hyperparathyroidism
HYPERPARATHYROIDISM

Hyperparathyroidism is a condition wherein there is an excessive production of parathyroid hormone (PTH).

Primary hyperparathyroidism is the most common endocrine disorder and an important cause of hypercalcemia in ambulatory patients.

Classic signs and symptoms include bone disease, kidney stones and hypercalcinosis.

Primary goal of pharmacological therapy is to normalize calcium levels.

 

Principles of Therapy

  • Goal: Normalize calcium levels
  • Recommended for the following individuals:
    • Mildly elevated serum calcium levels (<1 mg/dL above upper normal limit)
    • No previous life-threatening hypercalcemic episodes
    • Normal bone & renal status
    • Clinically asymptomatic, >50 years old
    • Poor surgical candidate
    • Inability to undergo surgery
    • Patient preference

Pharmacotherapy

Bisphosphonates

  • Potent inhibitor of bone resorption
  • Useful to improve low bone mass in patients w/ untreated PHPT
  • Recommended for patients w/ PHPT & osteoporosis or those w/ low bone mineral density warranting intervention who opted not to undergo surgery
  • Increases bone mineral density after short term (2 years) therapy
  • Alternative treatment in mild hypercalcemia due to PHPT

Alendronate

  • Given to patients w/ mild PHPT for 1-2 years
  • Increased bone density at the hip & lumbar spine but not radius
  • Studies showed 10 mg/day Alendronate effectively reverses bone loss in hyperparathyroidism

Pamidronate

  • Most effective for acute treatment of hypercalcemia associated w/ PHPT
  • Given intravenously
  • Cannot be used as long-term treatment due to poor gastrointestinal drug absorption,
  • PTH levels increases w/ increased renal tubular resorption & gastrointestinal calcium absorption

Calcimimetic

  • Inhibits PTH secretion by activating calcium-sensing receptor in parathyroid gland
  • Used for poor surgical candidates to normalize serum calcium in patients w/ severe hypercalcemia
  • Preferred over bisphosphonates for patients who are unable to have surgery & whose primary indication for surgery is symptomatic &/or severe hypercalcemia w/ normal bone density

Cinacalcet

  • Approved use in PHPT
  • Only approved calcimimetic for secondary hyperparathyroidism treatment
  • Used to treat hyperparathyroidism in ESRD patients on long-term dialysis
  • Oral administration peaks within 2-3 hours which lowers circulating PTH levels within the same period
  • Reduces serum calcium levels in PTCA patients particularly in unresectable diseases & those who underwent multiple operations without cure

Vitamin D & Analogues

  • Aggressive supplementation is recommended for secondary hyperparathyroidism patients due to vitamin D deficiency w/ normal renal function
  • Helps in suppression of the synthesis of PTH
  • Inhibits evolution of parathyroid hyperplasia
  • Adequate daily intake of 200 IU, 400 IU & 600 IU are recommended for adults up to 50 years, 51-70 years & ≥71 years respectively
  • For patients w/ vitamin D deficiency, 50,000 IU weekly for 8 weeks or 3000 IU daily Vitamin D2 supplementation or 1000 IU daily Vitamin D3 is recommended
  • Caution must be observed as to high doses can lead to hypercalcemia
  • Vitamin D analogues (Paricalcitol & Doxercalciferol) are less likely to cause hypercalcemia
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.